Rare ashy dermatosis‐like hyperpigmentation associated with osimertinib. Issue 9 (29th March 2022)

• Record Type: Journal Article
• Authors: Funai, Kazuhito
• Is Part Of: Thoracic cancer. Volume 13:Issue 9(2022)
• Page Start: 1436
• Page End: 1437
• Publication Date: 2022-03-29
• Subjects: ashy dermatosis‐like hyperpigmentation -- dermatological adverse event -- epidermal growth factor receptor‐tyrosine kinase inhibitor -- lung adenocarcinoma -- quality of life; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.14383
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR‐TKI and is widely used as the first‐line treatment for EGFR mutation‐positive non‐small cell lung cancer. Pigmentary changes caused by EGFR‐TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin‐related adverse event. Here, I report a case of osimertinib‐associated ashy dermatosis‐like hyperpigmentation on imaging. Although reducing the dose of osimertinib to 40 mg did not improve pigmentation, osimertinib use was continued due to its clinical and radiological benefit, which persisted for a long time. Abstract : Progressive darkening of the skin diagnosed by a dermatologist as osimertinib‐associated ashy dermatosis‐like hyperpigmentation.